Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025

Glucotrack, Inc.

2025-Q1 EPS reported -$0.67

Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.
R&D expense $1.9M (down $0.2M); MG&A $1.6M (up $0.8M on legal/professional fees).
Cash $9.1M at Mar 31, 2025 vs $5.6M at Dec 31, 2024; $6.4M from financing.
First patients in Australian CBGM feasibility study expected Q3 2025; FDA IDE pilot study expected Q4 2025.
First-in-human study met primary endpoint; no device-related serious adverse events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.